# Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

> **NCT07551804** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** Inpegsomatropin Injection
- **DRUG:** Placebo for Inpegsomatropin Injection
- **DRUG:** Inpegsomatropin Injection
- **DRUG:** Placebo for Inpegsomatropin Injection
- **DRUG:** Inpegsomatropin Injection
- **DRUG:** Placebo for Inpegsomatropin Injection

## Key facts

- **NCT ID:** NCT07551804
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551804, "Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07551804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*